CL-218,872 EU

6 - 52

Discover CL-218,872 – The Next Generation Sedative

Presentación de CL-218,872, a groundbreaking sedative-hypnotic offering unparalleled efficacy in inducing sleep and reducing anxiety. Unlike traditional benzodiazepines, CL-218,872 targets specific GABA A receptors, ensuring a focused approach with fewer side effects. Ideal for research and therapeutic applications, it’s a beacon of hope for those seeking reliable and safe sedation.

Este producto también está disponible en Cápsula y Gotas para facilitar la investigación.

Todos los productos de EU Retail sólo pueden enviarse a países de la UE.

Todas las drogas de diseño vendidas en este sitio web están destinadas a la investigación y a aplicaciones forenses.

 

Product Overview:

CL-218,872 is a novel sedative and hypnotic compound. Unlike traditional benzodiazepines, it belongs to a unique class of nonbenzodiazepine hypnotics. The compound is particularly noted for its selective action on the GABA A receptor, specifically targeting the α1 subtype.

Chemical and Pharmacological Properties:

The molecular structure of CL-218,872 differentiates it from benzodiazepines, contributing to its unique pharmacological profile. Its action as a partial agonist at the GABA A receptor sites leads to sedative, anxiolytic, anticonvulsant, and amnestic effects, with a reduced risk of dependency compared to traditional benzodiazepines.

Posología y administración:

The optimal dosage of CL-218,872 varies depending on the intended use and the subject’s physiology. In research settings, dosages are carefully controlled and monitored.

Therapeutic Effects:

CL-218,872 is primarily used in research for its sedative and hypnotic effects. It has shown potential in studies for inducing sleep and reducing anxiety, with a faster onset and shorter duration of action, making it advantageous for specific therapeutic applications.

Side Effects and Harm Reduction:

Like all sedative-hypnotics, CL-218,872 can cause side effects such as dizziness, confusion, and motor impairment. Long-term use or misuse can lead to tolerance and dependence. Its safety profile, however, indicates a lower risk of these adverse effects compared to traditional benzodiazepines. Harm reduction strategies involve controlled administration, monitoring for adverse reactions, and avoiding use with other central nervous system depressants.

Comparative Analysis:

In comparison to other hypnotics like triazolam or zolpidem, CL-218,872 offers a unique balance of efficacy and safety, making it a subject of interest in both pharmacological research and potential clinical use.

Por qué comprar CL-218,872 EU from RECHEMCO?

★ Contamos con una larga trayectoria comercial en el mercado para que usted se beneficie de nuestra experiencia.
★ CL-218,872 fue probado y verificado.
★ We accept various payment methods such as Bitcoin, Monero, many other cryptocurrencies and bank wire.

Qué recibirá al comprar CL-218,872 EU from RECHEMCO?

- Una bolsa de papel de aluminio sellada que contiene CL-218,872 EU
• White powder
• 98-99% Purity

Cantidad

50 mg, 100 mg, 250 mg, 500 mg, 1 g

Reseñas

Aún no hay opiniones.

Sé el primero en opinar "CL-218,872 EU"

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

GIRAR PARA GANAR

  • Pruebe suerte y gane un código de cupón de descuento
  • 1 tirada gratis cada 15 días
  • No hagas trampas. Por favor, utilice sólo su dirección de correo electrónico real.
  • RECUERDE: La validez del código de cupón es de 7 días.
Pruebe suerte
Nunca
Recordar más tarde
No, gracias.